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Abstract Tissue plasminogen activator (t-PA) has a short
therapeutic time window for administration (3 h) and
carries a risk of promoting intracerebral hemorrhage. The
aim of the present study was to investigate a therapeutic
time window and frequency of hemorrhagic region by
treatment with Stachybotrys microspora triprenyl phenol-7
(SMTP-7). Thrombotic occlusion was induced by transfer
of acetic acid-induced thrombus at the right common
carotid artery into the brain of mice. Infarction area,
neurological score, edema percentage, and regional cerebral
blood flow (CBF) were determined as the index of the
efficacy of SMTP-7. In order to evaluate the mechanism of
SMTP-7, plasmin activities and the expressions of inter-
leukin (IL)-1β, tumor necrosis factor-α (TNF-α), and IL-6
mRNA were examined. SMTP-7 (0.1, 1, 10 mg/kg) dose
dependently reduced infarction area, neurological score,
and edema percentage. Additionally, its therapeutic time
window was longer than that of t-PA, a high-molecular-
weight compound. In addition, little hemorrhagic region
was induced by treatment with SMTP-7. SMTP-7 showed
plasmin activity in vivo and caused a decreased CBF to
recover. Furthermore, the expressions of inflammatory
cytokine mRNA (IL-1β, TNF-α, IL-6) were increased by
t-PA treatment 3 h after ischemia but were not induced by
SMTP-7 treatment. These results indicate that SMTP-7
shows potential thrombolytic and anti-inflammatory effects
as well as a wide therapeutic time window and little
hemorrhagic region compared with that of t-PA. Therefore,
this novel low-molecular-weight compound may represent
a novel approach for the treatment of cerebral infarction.
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Introduction
The triprenyl phenol staplabin (Shinohara et al. 1996) is the
first low-molecular-weight compound that enhances both
plasminogen–fibrin binding and the activation of plasmin-
ogen by relaxing the plasminogen conformation (Takayasu
et al. 1997). Conformational modulation of plasminogen is
thus an attractive means to regulate the localized plasmin-
ogen/plasmin system. Stachybotrys microspora IFO 30018
produces a variety of staplabin analogs (SMTPs) (Koyama
et al. 1997; Hasumi et al. 1998), some of which are found
to be several times as active as staplabin
4. In particular,
Stachybotrys microspora triprenyl phenol-7 (SMTP-7;
Orniplabin, MW 869.1, Fig. 1) is five to ten times more
potent than staplabin in enhancing plasminogen–fibrin
binding, urokinase-catalyzed activation of plasminogen,
and urokinase and plasminogen-mediated fibrin degrada-
tion (Hu et al. 2000).
Ischemic brain injury and subsequent cell death lead to
long-term disabilities, such as paralysis, speech, and
memory deficits and possibly death. Stroke is clearly a
serious issue. There is limited satisfaction with drug therapy
in this area because thrombolytic therapy can unfortunately
only be used in a relatively low percentage of patients (The
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PA Stroke Study Group 1995; Wardlaw et al. 2003). Tissue
plasminogen activator (t-PA), a high-molecular-weight
compound, is the only approved therapy for acute stages
in stroke. However, t-PA has a short therapeutic time
window for administration (3 h) and carries a risk of
promoting intracerebral hemorrhage (The National Institute
of Neurological Disorders, and Stroke rt-PA Stroke Study
Group 1997). Therefore, a method is needed to reduce t-
PA-induced hemorrhage and extend the therapeutic time
window for safe and effective reperfusion to limit cerebral
damage. This is an important medical need. Several studies
suggest that combination therapy with neuroprotective
drugs may extend the t-PA treatment time window in
embolic stroke (Okubo et al. 2007; Zhang et al. 2004;
Murata et al. 2008). A large number of drugs have been
developed but failed to expand the therapeutic time window
and protect against reperfusion cerebral damage with
single-agent administration.
Ischemic hypoxic brain injury often causes irreversible
brain damage. The cascade of events leading to neuronal
injury and death in ischemia includes the release of
cytokines and free radicals, and induction of inflammation,
apoptosis, and excitotoxicity (Kuroda and Siesjo 1997).
When a tissue is subjected to ischemia and reperfusion, pro-
inflammatory cytokines produced by inflammatory cells
can trigger the adhesion and migration of circulating
neutrophils to endothelial cells and the generation of
reactive oxygen species (ROS) that enhance neutrophil
infiltration and result in ischemic injury (Liou et al. 2003).
Our goal is to develop an effective agent for treating
cerebral infarction even by single-agent administration. We
consider this to be an appropriate goal for helping many
patients with embolic cerebral infarction. To achieve this
goal, it is necessary to identify a novel compound that has
dual activities of thrombolytic activity and an anti-
inflammatory effect. Therefore, it is important that the
mechanism of this drug is not limited to one factor but
involves many mechanisms, most of which may be
interrelated.
The aim of the present study was to investigate a
therapeutic time window and frequency of hemorrhagic
region by the treatment with SMTP-7. As a result, the
present study demonstrated, for the first time, that SMTP-7
has a wide therapeutic time window and little hemorrhagic
region in an embolic cerebral infarction model through its
thrombolytic activity and anti-inflammatory effects.
Materials and methods
Materials
Sample buffer for fibrin zymography consisted of 125 mM
of Tris-HCl, pH 6.8, 4% (w/v) sodium dodecyl sulfate
(SDS), 0.04% (w/v) bromophenol blue, and 20% (w/v)
sucrose. Acetylsalicylic acid (ASA) and 2,3,5-triphenylte-
trazolium chloride (TTC) were purchased from Wako Pure
Chemical (Osaka, Japan). Isoflurane (Escain®) was pur-
chased from Mylan (Tokyo, Japan). SuperScript VILO
cDNA Synthesis Kit, SYBR Green reagent system and
TRIzol were purchased from Invitrogen (Carlsbad, CA,
USA). The t-PA (Activacin®) was purchased from Kyowa
Hakko Kirin (Tokyo, Japan).
Animals
Male ddY mice weighing 35–45 g (Saitama Jikken Co.,
Ltd., Saitama) were used. All experiments were conducted
under the regulations of the Committee of Animal Care and
Welfare of Showa University. Mice were maintained in an
air-conditioned animal room at 20±2°C, with 50±20%
relative humidity and a 12-hr light–dark cycle (lights on
from 0800 to 2000 hours). The mice received a standard
laboratory diet; in addition, water was provided ad libitum.
Embolic infarction model
The embolic infarction model was induced as described
previously (Hashimoto et al. 2010) .T h em i c ew e r e
anesthetized with 5% isoflurane, and anesthesia was
maintained with 1.5% isoflurane. The right common carotid
artery (RCCA) was exposed carefully from the surrounding
tissue. The RCCA was temporarily clamped using an
aneurysm clip, and acetic acid was applied to generate a
thrombus. After 10 min, the clip was removed, and the
thrombus was transferred to the brain for embolization by
the bloodstream. To evaluate the effect of surgical prepa-
ration, the same surgically operated mice without applica-
tion of acetic acid were served as the sham-operated group.
The control group was administered vehicle. Body temper-
ature was maintained at 37°C during surgery with a
heating lamp.
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Fig. 1 Structure of SMTP-7 (Orniplabin; CAS registry No. 273379-
50-3)
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Twentyfourhoursafterischemia,theneurologicalscoreswere
determined by a modified method described by Longa et al.
(1989): no deficit, 0; failure to extend right hind limb fully, 1;
circling to the right, 2; failing to the left, 3; no spontaneous
walking with a depressed level of consciousness, 4.
Lesion size and brain swelling
The animals were killed after the evaluation of neuro-
logical scores. The brains were cut into 2-mm coronal
slices starting at 1 mm from the frontal pole. The first
and second slices were incubated with 2% TTC in saline
for 30 min at 37°C. The TTC-unstained white area of the
whole brain and the whole brain of each posterior face of
the slice were measured by Image J software (version
1.40, NIH, Bethesda, MD, USA) and were numerically
integrated across the thickness of the slice to obtain an
estimate of the infarct volume and the whole brain volume,
respectively. The volumes from all slices were summed to
calculate the total infarct volume and were expressed as the
percentage of the whole brain volume infarct volume ½
of whole brain ¼ infarct volume of whole brain=volume ð
of whole brainÞ 100 . The degree of edema was calcu-
lated as follows: edema percent ¼ volume of potischemic ð ½
hemisphere   volume of contralateral hemisphereÞ=volume
of contralateral hemisphere   100 .
Evaluation of hemorrhagic transformation
The multifocal cerebral hemorrhages on the macroscopic
brains were visually determined by consensus (K.S., T. H.).
The rate of hemorrhage was calculated as the number of
hemorrhagic cases divided by the total number of cases in
each group.
Treatment protocol
The mice with cerebral infarction were randomly assigned to
either the vehicle-treated group, SMTP-7-treated group, or
t-PA-treated group. SMTP-7 was intravenously infused at
doses of 0.1, 1, and 10 mg/kg as a 10% bolus and the
remainderwascontinuouslyinfusedata30-minintervalusing
a syringe pump (KDS200P, MUROMACHI KIKAI, Tokyo,
Japan) at 1 h after embolization (n=6). In other experiments,
10 mg/kg of SMTP-7 and t-PAwere infused at 1 or 3 h after
the embolization described above(n=6, with exception of
three experiments of cerebral blood flow). Previously, we
confirmed that SMTP-7 and t-PA dose dependently inhibited
the infarct area and neurological score in acetic acid-induced
embolic cerebral model of the Mongolian gerbil and
significant differences were observed at 10 mg/kg (i.v.)
(Hashimoto et al. 2010). Therefore, we selected at 10 mg/kg
in the present study. 10 mg/kg of ASA was infused as a
bolus at 3 h after embolization just before t-PA administra-
tion (n=6).
Fibrinogen zymography
Each blood sample was withdrawn in 3.8% trisodium citrate
solution [1/9 (v/v) ]a t0 ,1 ,a n d3ha f t e rS M T P - 7o rt - P A
administration. The sample was centrifuged (5,000 rpm;
15 min; 4°C) and the plasma was stored with a sample buffer
at −80°C until use. Zymography was performed with 7.5%
SDS-polyacrylamide gel containing 2 mg/mL of fibrinogen.
In this technique, each plasma sample was diluted 300-fold
with distilled water and mixed with the SDS-polyacrylamide
gel electrophoresis sample buffer without a reducing agent.
Then, the samples were subjected to electrophoretic analysis
at 4°C. The gels were sequentially washed twice in 2.5%
Triton X-100 and incubated for 48 h in 0.1 M glycine and
50 mM of Tris-HCl (pH 8.3) at 37°C, stained for 30 min in
Coomassie Brilliant Blue (CBB) R-250, and destained in
acetic acid–methanol–water (1:1:6). Fibrinolytic activity was
identified as negative staining with CBB R-250 and
expressed as percentage of the positive control activity.
Laser Doppler perfusion imaging
CBFwasdeterminedbylaserDopplerflowmetry(MoorFLPI,
Moor Instruments Ltd., UK). CBF was measured before
embolic infarction (100% baseline), after embolic infarction,
and at 0, 1, 3, and 24 h after injection of t-PA or SMTP-7 in
accordance with the manufacturer's instructions. The laser
Doppler signal of the scanning image was analyzed using the
MoorFLPI software (version 2.1). This software enables
analysis of perfusion value profiles within a region of
interest in circular areas of the same size containing the
same number of pixels. Then, CBF was expressed as
percentage of the pre-ischemic value.
Real-time reverse transcription-PCR analysis
Total RNA was isolated from the right and left sides of the
third brain slice using the TRIzol method in accordance with
the manufacturer's instructions. cDNA was generated from
the RNA samples (1 μg) using a SuperScript VILO cDNA
synthesis kit. Target cDNA levels were quantified by real-
time reverse transcription-PCR (RT-PCR) using the ABI
PRISM 7000 Sequence Detector (Applied Biosystems,
Foster City, CA, USA) utilizing the SYBR green reagent
system. The forward primer for β-actin was 5′-
CCTTCCTTCTTGGGTATGGAATC-3′ and the reverse
primer was 5′-TGCTAGGAGCCAGAGCAGTAATC-3′.
The primers of interleukin (IL)-1β, tumor necrosis factor-α
Naunyn-Schmied Arch Pharmacol (2010) 382:245–253 247(TNF-α), and IL-6 were purchased from Qiagen (Tokyo,
Japan; QuantiTect Primer Assays) for mouse IL-1β
(QT01048355), TNFα (QT00104006), and IL-6
(QT00098875). The thermal profile for the real-time RT-
PCR was carryover prevention at 50°C for 2 min and initial
activation step at 95°C for 15 min followed by 40 cycles of
denaturation at 94°C for 15 s, annealing at 55°C for 30 s,
and extension at 72°C for 30 s. Using the standard curve for
the target of interest, relative copy number values can be
determined for any unknown sample. The relative amount of
each factor transcript was normalized to the amount of β-
actin transcript in the same cDNA.
Statistical analysis
All data are expressed as the mean±SEM. The statistical
significance of a non-parametric test (neurological score)
was determined by Steel test. Analysis of hemorrhage was
done using the Fischer's exact test. The other statistical
significance was evaluated with the one-way ANOVA
followed by Bonferroni testing. P<0.05 was considered
statistically significant.
Results
Dose dependence of the effect of SMTP-7
Figure 2 illustrates the dose dependence of the effect of
SMTP-7 in an acetic acid-induced embolic cerebral
infarction model. Infarction area, neurological score, and
edema percentage in the control group were 11.9±2.54,
3.16±0.477, and 13.2±1.76, respectively. These values
were significantly different from those of the sham-
15
10
5
0
I
n
f
a
r
c
t
i
o
n
 
a
r
e
a
 
(
%
) 4
3
2
1
0
N
e
u
r
o
l
o
g
i
c
a
l
 
s
c
o
r
e 15
10
5
0
E
d
e
m
a
 
p
e
r
c
e
n
t
a
g
e
 
(
%
)
Sham Cont   0.1      1       10
SMTP-7 (mg/kg)
Sham Cont   0.1      1       10
SMTP-7 (mg/kg)
Sham Cont   0.1      1       10
SMTP-7 (mg/kg)
*
**
* **
Fig. 2 Concentration dependency of SMTP-7 on infarction area,
neurological score, and edema percentage in embolic infarction model.
SMTP-7 was administered at 1 h after ischemia. The values were
obtained at 24 h after ischemia. Data represent the mean±SEM of six
experiments. *P<0.05, **P<0.01, statistically significant difference
from control group
* *
control
t-PA
12
1 cm
SMTP-7
Slice No.
15
10
5
0
I
n
f
a
r
c
t
i
o
n
 
a
r
e
a
 
(
%
) 4
3
2
1
0
N
e
u
r
o
l
o
g
i
c
a
l
 
s
c
o
r
e 15
10
5
0
E
d
e
m
a
 
p
e
r
c
e
n
t
a
g
e
 
(
%
)
** **
** **
*
**
a
b
Cont      1             3 
SMTP-7
Control
t-PA
Time (hr)
t-PA + ASA
*
Cont      1             3 
Time (hr)
Cont      1             3 
Time (hr)
Fig. 3 a Comparison of TTC-
stained cerebral sections
obtained from SMTP-7 and t-
PA-treated embolic infarction
models. The drugs were admin-
istered at 3 h after ischemia.
Cerebral tissue was taken at 24 h
after ischemia. b Comparative
study of therapeutic time win-
dow in embolic infarction mod-
el. SMTP-7 and t-PA were
administered at 1 or 3 h after
ischemia. ASA was adminis-
tered with t-PA at 3 h after
ischemia. The values were
obtained at 24 h after ischemia.
Data represent the mean±SEM
of six experiments. *P<0.05,
**P<0.01, statistically signifi-
cant difference from control
group
248 Naunyn-Schmied Arch Pharmacol (2010) 382:245–253operated group. On the other hand, SMTP-7 ameliorated
the size of the infarction area in a dose-dependent manner.
Inhibition rates were 58.8% at 1 mg/kg and 78.9% at
10 mg/kg. There were statistically significant differences
between the control group and the SMTP-7-treated group at
1 mg/kg (P<0.05) and 10 mg/kg (P<0.01). The neurolog-
ical score and edema percentage were also improved by
treatment with SMTP-7 at 10 mg/kg. Inhibition rates were
47.6% on neurological score and 58.5% on edema
percentage. Significant differences were observed at
10 mg/kg (neurological score, P<0.05; edema percentage,
P<0.01).
Extension of therapeutic time window
The next investigation compared the therapeutic time
window for SMTP-7 with that for t-PA. Representative
photographs of brain slices taken from mice subjected to
SMTP-7 and t-PA treatments 3 h after ischemia are shown
in Fig. 3a. In the t-PA-treated group at 3 h after ischemia, a
clear infarction area was observed at the cerebral hemi-
sphere affected by embolization. In contrast, the infarction
area was not visible at 3 h after ischemia in the SMTP-7-
treated group. The changes in infarction area, neurological
score, and edema percentage over time are shown in
Fig. 3b. Although t-PA ameliorat e de a c hv a r i a b l eb y
administration at 1 h after ischemia, its effect gradually
decreased time-dependently. However, the effects of
SMTP-7 on cerebral infarction area, neurological score,
and edema percentage were maintained by administration at
3h after ischemia. There were significant differences be-
tween the SMTP-7-treatedandcontrol groups at all points. A
combination of t-PA and ASA partially ameliorated the
infarction area, neurological score, and edema percentage by
treatment at 3 h after ischemia.
Hemorrhagic formation
Figure 4 illustrates the hemorrhagic formation. In the case
of treatment with t-PA (10 mg/kg), the hemorrhagic
SMTP-7
t-PA
Hemorrhage
SMTP-7
No. of hemorrhage/total
t-PA
1/13
7/14
a
b
Parietal region
Control
Thrombus
Control 5/18
Group
*
Fig. 4 a Comparison of the
hemorrhagic formation in a pa-
rietal region obtained from
SMTP-7 and t-PA-treated em-
bolic infarction models. The
brain was taken at 24 h after
ischemia. b Comparison of the
frequency of hemorrhagic for-
mation obtained from SMTP-7
and t-PA-treated embolic infarc-
tion model. *P<0.05, statisti-
cally significant difference
between SMTP-7 and t-PA-trea-
ted groups
Naunyn-Schmied Arch Pharmacol (2010) 382:245–253 249formation was observed in a parietal region and the number
of hemorrhage was 7/14. However, there was little
hemorrhagic region by the treatment with 10 mg/kg
SMTP-7 (1/13). There is a statistically significant difference
between the SMTP-7- and t-PA-treated groups (P<0.05).
Fibrinolytic activity
Figure 5 shows the fibrinolytic activity in mice plasma after
SMTP-7 and t-PA administrations. SMTP-7 caused a
significant increase in fibrinolytic activity of about 3.5-fold
at 1 and 3 h after administration (P<0.01). On the other
hand, t-PA exhibited a significantly greater increase in
fibrinolytic activity at 0 h after administration (P<0.01).
However, the activity gradually decreased time-
dependently. At 3 h after administration, the fibrinolytic
activity of SMTP-7 was higher than that of t-PA.
Change in CBF
After embolization, CBF of the ipsilateral hemisphere
markedly fell to about 30% of the pre-ischemic value in
all groups. In the control group, CBF of the ipsilateral
hemisphere was maintained until 24 h later. However, CBF
of the ipsilateral hemisphere after SMTP-7 administration
gradually recovered time-dependently. At 24 h after SMTP-
7 administration, CBF of the ipsilateral hemisphere recov-
ered up to 76% of the pre-ischemic value. There were
statistically significant differences between the post-
ischemic value and at 24 h after SMTP-7 administration
(P<0.05). On the other hand, in the t-PA-treated group,
CBF of the ipsilateral hemisphere quickly recovered at 1 h
after t-PA administration. There were statistically signifi-
cant differences between the post-ischemic value and at 1,
3, and 24 h after t-PA administration (P<0.05) (Fig. 6a, b).
Figure 6c illustrates the change in CBF of the ipsilateral
hemisphere by t-PA administration at 1 or 3 h after
ischemia. No significant difference in the recovery of
CBF of the ipsilateral hemisphere was observed in a
comparison between the two groups. Figure 6d illustrates
the change in CBF of the ipsilateral hemisphere by SMTP-7
administration at 1 or 3 h after ischemia. No significant
difference in the recovery of CBF of the ipsilateral
hemisphere was also observed in a comparison between
the two groups.
Contribution of inflammation
Figure 7 expresses the real-time RT-PCR analysis for IL-
1β, TNF-α, and IL-6. In the control group, the levels of the
TNF-α (P<0.01) and IL-6 (P<0.05) mRNA expression
were significantly higher in the ipsilateral hemisphere
compared with the sham-operated group. In the case of
treatment with t-PA, the expression levels of IL-1β, TNF-α,
and IL-6 were not enhanced by administration at 1 h after
ischemia. However, the administration of t-PA at 3 h after
ischemia significantly enhanced the expressions of IL-1β,
TNF-α, and IL-6 (P<0.01). In contrast, the expression
levels of IL-1β, TNF-α, and IL-6 were not increased by the
treatment with SMTP-7 not only at 1 h but also at 3 h after
ischemia. A combination of t-PA and ASA partially
ameliorated inflammatory cytokine mRNA by treatment at
3 h after ischemia. No changes in these levels of mRNA
expression were observed in the contralateral hemisphere.
Discussion
We report here that SMTP-7 ameliorates embolic infarction
and that its efficacy is greater than that of t-PA. This is the
first low-molecular-weight compound with dual activities
of thrombolytic and anti-inflammatory activity. We theo-
rized that this compound overcomes the weakness of t-PA,
namely, its narrow therapeutic time window. The risk of
cerebral hemorrhage may limit the therapeutic time window
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Fig. 5 Fibrinolytic activity of SMTP-7 and t-PA-treated embolic
infarction models at 0, 1, and 3 h after drug administration. Drugs
were administered at 1 h after ischemia. Fibrinolytic activity was
identified as negative staining with CBB R-250 and expressed as a
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250 Naunyn-Schmied Arch Pharmacol (2010) 382:245–253of t-PA. In the present study, SMTP-7 showed an extended
therapeutic time window (Fig. 3). Therefore, the problem of
a narrow therapeutic time window may be resolved by
SMTP-7 administration. On the other hand, t-PA carried
hemorrhagic formation. However, little hemorrhagic region
was induced by treatment with SMTP-7 (Fig. 4). Because
plasminogen is activated on the surface of cells and the
embolus, the effect of SMTP-7 is based on a physiological
process. In other words, this compound enables the local
amplification of plasmin at the sites at which generation is
needed. This is one reason why SMTP-7 appears to cause
less hemorrhage.
Control
SMTP-7
High
Low
t-PA
Pre                    Post                    0 hr                  1 hr                    3 hr                   24 hr
120
100
80
60
40
20
0
C
B
F
 
(
%
 
o
f
 
p
r
e
)
Pre Post    0       1              3                            24
Time (hr)
Control
SMTP-7
t-PA
* *
*
*
a
b
120
100
80
60
40
20
0
C
B
F
 
(
%
 
 
o
f
 
p
r
e
)
Pre  Post   0       1              3                            24
Time (hr)
1 hr
3 hr
* *
*
*
*
c
d
Pre  Post   0       1              3                            24
Time (hr)
1 hr
3 hr
*
**
120
100
80
60
40
20
0
C
B
F
 
(
%
 
 
o
f
 
p
r
e
)
Fig. 6 Change in CBF in em-
bolic infarction model over time.
a Pseudocolor images of cere-
bral tissue. Color bar indicates
CBF. b Change in CBF over
time. SMTP-7 and t-PA were
administered at 1 h after ische-
mia. c Comparison of change in
CBF over time. The t-PA was
administered at 1 or 3 h after
ischemia. d Comparison of
change in CBF over time.
SMTP-7 was administered at 1
or 3 h after ischemia. CBF was
measured before embolic in-
farction (pre, 100% baseline),
after embolic infarction (post),
and at 0, 1, 3, and 24 h after
administration. CBF was
expressed as a percentage of the
pre-ischemic value. Data repre-
sent the mean±SEM of three
experiments. *P<0.05,
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cant difference from each post
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Naunyn-Schmied Arch Pharmacol (2010) 382:245–253 251As shown in Fig. 5, we demonstrated that SMTP-7 had
fibrinolytic activity in vivo. However, its activity is less
than that of t-PA. In spite of lower fibrinolytic activity, the
CBF of the ipsilateral hemisphere significantly recovered at
24 h after SMTP-7 administration (Fig. 6b). The discrep-
ancy between fibrinolytic activity and recovery of CBF
may be explained by different effector sites for the two
drugs. SMTP-7 promotes conversion to plasmin by a
conformational change of plasminogen with a plasminogen
activator (Koyama et al. 1997). Because plasminogen is
activated on the surface of cells and the embolus, this
compound enabled local amplification of plasmin at the
sites where it was needed. This is one reason why SMTP-7
caused full recovery of the CBF; at the same time, less
hemorrhage appeared to occur. This feature of SMTP-7 is
advantageous for the treatment of cerebral infarction. In
addition, SMTP-7 is effective even when administered at
3 h after ischemia, although t-PA hardly had any effects.
When t-PA was administered at 3 h after ischemia,
reperfusion damage of cerebral tissue may occur because
CBF recovers like that upon its administration at 1 h after
ischemia (Fig. 6c). On the other hand, when SMTP-7 was
administered at 3 h after ischemia, reperfusion damage of
cerebral tissue did not occur.
Reperfusion of occluded vessels leads to the production
of ROS. ROS can stimulate ischemic cells to secrete
various inflammatory cytokines. IL-1β and TNF-α are
cytokines that initiate the inflammatory response. IL-1β
mRNA expression is increased at early reperfusion (1 h)
and subsequently (6–24 h) (Davies et al. 1999). TNF-α is
also upregulated in the brain after ischemia with a similar
expression pattern to IL-1β (Murakami et al. 2005). IL-6 is
thought to be a pro-inflammatory cytokine. The mRNA
expression of these cytokines was enhanced by treatment
with t-PA at 3 h after ischemia. In contrast, no significant
increase in the mRNA expression of these inflammatory
cytokines was observed by treatment with SMTP-7 at 3 h
after ischemia (Fig. 7). In other words, reperfusion damage
of cerebral tissue does not occur in the case of SMTP-7
treatment. This is also an important advantage over t-PA
treatment. Combined administration with other drugs is
unnecessary if SMTP-7 is used for the treatment of cerebral
infarction. It is unclear from the present study why SMTP-7
suppresses inflammatory cytokine mRNA expression. Ad-
ditional studies are required to clarify the precise mecha-
nism involved.
As described above, upon treatment with t-PA at 3 h
after ischemia, reperfusion damage was observed. At later
times after ischemia, many kinds of gene induction occur
(Koistinaho and Hokfelt 1997), some of which are also
known to be involved in the brain inflammation that is a
major factor in the progression of injury (Dirnagl et al. 1999;
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Fig. 7 Comparative study of
mRNA expression of IL-1β,
TNF-α, and IL-6. SMTP-7 and
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combination of t-PA and ASA confers additional neuro-
protection against reperfusion damage by treatment at 3 h
after ischemia. The infarction area, neurological score,
edema percentage, and inflammatory cytokine mRNA were
partially ameliorated by this combination (Figs. 3b, 7).
Therefore, we hypothesized that a few advantage was
expected by combination therapy of t-PA and non-steroidal
drug. Then, the novel drug having dual activity like a SMTP-
7 is needed.
Many therapeutic agents show effectiveness in preclin-
ical study using a small animal model but fail to exhibit
positive effects in humans. As such, the stroke therapy
academic industry roundtable meeting recommended that
the evaluation of stroke recovery drugs should be con-
ducted with a gyrencephalic species, namely, one that is
similar to humans, for example, macaque monkeys (Stroke
Therapy Academic Industry Roundtable 1999). We are also
evaluating the effect of SMTP-7 using a thrombotic middle
cerebral artery occlusion model in cynomolgus monkeys.
We obtained positive effects nowadays. We will submit this
observation in the future.
In summary, we demonstrated that SMTP-7 had suffi-
cient efficacy, a wide therapeutic time window, and little
hemorrhagic region compared with t-PA. This compound is
the first low-molecular-weight compound with dual activ-
ities of thrombolytic and anti-inflammatory activity. The
excellent therapeutic time window and little hemorrhagic
region of SMTP-7 may have contributed to both activities.
Therefore, SMTP-7 may represent a novel approach to the
treatment of cerebral infarction.
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